Binds Enzyme Patents (Class 424/146.1)
-
Publication number: 20140127190Abstract: Described herein are peptides from secretory phospholipase A2-IB and antibodies that can be used to reduce the contribution of the gastrointestinal tract to inflammatory processes including systemic inflammatory responses. Specifically, antibodies that bind specifically a peptide from secretory phospholipase A2-IB prevent death in a mouse model of LPS-induced endotoxemia. The antibodies described herein are particularly useful to treat systemic inflammatory response syndromes, including sepsis.Type: ApplicationFiled: November 2, 2012Publication date: May 8, 2014Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Jordan Marshall Sand, Mark Eric Cook, Daniel Elmer Butz
-
Patent number: 8715672Abstract: The present invention relates to the use of at least one antibody and/or one inhibitor for inhibiting factor XII and for preventing the formation and/or the stabilization of three dimensional thrombi. It also relates to a pharmaceutical formulation and the use of factor XII as an anti-thrombotic target.Type: GrantFiled: December 21, 2012Date of Patent: May 6, 2014Assignee: CSL Behring GmbHInventors: Bernhard Nieswandt, Thomas Renne
-
Methods for treating conditions mediated by the inflammatory cytokine cascade using GAPDH inhibitors
Patent number: 8715658Abstract: The present invention is directed to a method of treating a subject at risk for or having a condition mediated by an inflammatory cytokine cascade comprising administering to the subject an amount of a GAPDH inhibitor effective to treat the subject at risk for or having a condition mediated by an inflammatory cytokine cascade.Type: GrantFiled: August 17, 2010Date of Patent: May 6, 2014Assignee: The Feinstein Institute for Medical ResearchInventors: Kevin Tracey, William Parrish -
Patent number: 8710192Abstract: The present invention provides antibody antagonists against proprotein convertase subtilisin/kexin type 9a (“PCSK9”) and methods of using such antibodies.Type: GrantFiled: December 10, 2010Date of Patent: April 29, 2014Assignees: IRM LLC, Novartis AGInventors: Sarah Rue, Steve B. Cohen, Jun Li, David Yowe
-
Patent number: 8709422Abstract: The invention provides a method for treating a medical condition, disease, or disorder mediated by a misfolded form of superoxide dismutase (SOD) in a subject in need of treatment. The method optionally comprises administering to the subject a composition comprising a pharmaceutically acceptable vehicle and an agent selected from (1) an exogenous antibody or fragment thereof that binds selectively to the misfolded form of SOD, and/or (2) an immunogen that elicits production of an endogenous antibody that binds selectively to the misfolded form of SOD, and/or (3) a nucleic acid sequence encoding (1) or (2).Type: GrantFiled: December 24, 2010Date of Patent: April 29, 2014Assignee: Amorfix Life Sciences Ltd.Inventors: Neil R. Cashman, Joachim Bernhard Ostermann, Avijit Chakrabartty, Rishi Rakhit
-
Patent number: 8697078Abstract: The present application relates to antibodies which recognize [2(2-aminoethylcarbomoyl)-ethoxymethyl]-tris-[2-N-(3-imidazol-1-yl-propyl))-ethoxymethyl]methane, a hapten molecule which closely mimics the local structure and conformation of the reactive zinc site in matrix metalloproteinases. An antibody is disclosed which comprises an antigen recognition region which comprises six CDR amino acid sequences selected from the group consisting of SEQ ID NOs: 4-15. Uses thereof are also disclosed.Type: GrantFiled: January 27, 2011Date of Patent: April 15, 2014Assignee: Yeda Research and Development Co. Ltd.Inventors: Irit Sagi, Netta Sela-Paswell, Tamar Danon, Raanan Margalit
-
Publication number: 20140099323Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: ApplicationFiled: October 30, 2013Publication date: April 10, 2014Inventors: OLLE HERNELL, SUSANNE LINDQUIST, LENNART GUSTAV LUNDBERG
-
Publication number: 20140093513Abstract: The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.Type: ApplicationFiled: May 24, 2013Publication date: April 3, 2014Applicant: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Chi B. Vu
-
Publication number: 20140093494Abstract: It is demonstrated that alpha synculein toxicity such as ?-synuclein mediated cell death, and alpha synuclein induced reactive oxygen species (ROS) in a cell requires proapoptotic endonuclease G and that the deletion of the endonuclease G or suppressing of the endonuclease G apoptotic pathway attenuates or counteracts such alpha synuclein toxicity. In view of these observations, compositions and methods for inhibition of ?-synuclein toxicity are provided. The inhibiting ?-synuclein toxicity can be used in methods for the treatment of synucleinopathies, such as Parkinsons disease (PD), dementia with Lewy bodies (DLB), pure autonomic failure (PAF), and multiple system atroypy (MSA) and the manufacture of medicaments for such treatment.Type: ApplicationFiled: August 21, 2013Publication date: April 3, 2014Applicants: University of Graz, Katholieke Universiteit LeuvenInventors: Veerle Baekelandt, Sabrina Buettner, Frank Madeo, Joris Winderickx
-
Patent number: 8680152Abstract: The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.Type: GrantFiled: May 2, 2012Date of Patent: March 25, 2014Assignee: Virobay, Inc.Inventor: Robert Booth
-
Patent number: 8679503Abstract: The present invention includes compositions and methods for the treatment of inflammatory disease (e.g., asthma, COPD, inflammatory bowel disease, atopic dermatitis, atopy, allergy, allergic rhinitis, scleroderma, and the like), relating to inhibiting a chitinase-like molecule. The invention further includes methods to identify new compounds for the treatment of inflammatory disease, including, but not limited to, asthma, COPD and the like. This is because the present invention demonstrates, for the first time, that expression of IL-13, and of a chitinase-like molecule, mediates and/or is associated with inflammatory disease and that inhibiting the chitinase-like molecule treats and even prevents, the disease. Thus, the invention relates to the novel discovery that inhibiting a chitinase-like molecule treats and prevents an inflammatory disease.Type: GrantFiled: July 12, 2010Date of Patent: March 25, 2014Assignee: Yale UniversityInventors: Jack A. Elias, Zhou Zhu
-
Publication number: 20140056964Abstract: Methods of promoting wound healing in a subject is disclosed. The method include applying a Granzyme B (Granzyme B) inhibitor to the wound. The wound may be a skin wound. The Granzyme B inhibitor may be comprised of nucleic acids, or peptides, including but not limited to antibodies, or small molecules.Type: ApplicationFiled: December 6, 2011Publication date: February 27, 2014Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventors: Paul R. Hiebert, Darryl A. Knight, David J. Granville, Wendy A. Boivin, Dawn M. Cooper
-
Patent number: 8642041Abstract: The present invention relates to the use of Adenylyl Cyclase-Associated Protein (CAP1) as a target for immuno-modulation. More specifically, the invention relates to the use of compounds that interact and bind CAP1, specifically, anti-CAP1 antibodies, and/or to CAP1 molecule or any fragments thereof, for the treatment of immune-related disorders by modulation of the Th1/Th2 balance. The invention further provides screening method for immuno-modulatory compounds that interact with CAP1.Type: GrantFiled: March 21, 2010Date of Patent: February 4, 2014Assignee: Protab Ltd.Inventors: Yaakov Naparstek, Eli Moallem
-
Patent number: 8642035Abstract: The present invention provides improved antibodies or antigen-binding molecules that specifically recognize and agonize the tyrosine receptor kinase B (TrkB) receptor, and methods of their use. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.Type: GrantFiled: January 16, 2009Date of Patent: February 4, 2014Assignee: IRM LLCInventor: Kenneth R. Luehrsen
-
Publication number: 20140030270Abstract: The present invention relates to methods of treating or preventing cholesterol related disorders, such as hypercholesterolemia, hyperlipidemia or dyslipidemia, using antibodies against proprotein convertase subtilisin/kexin type 9 (PCSK9). Formulations and methods of producing said formulations are also described.Type: ApplicationFiled: May 2, 2013Publication date: January 30, 2014Applicant: Amgen Inc.Inventor: Amgen Inc.
-
Publication number: 20140017245Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: ApplicationFiled: July 22, 2013Publication date: January 16, 2014Applicant: Allergan, Inc.Inventors: Michael E. Stern, Christopher S. Schaumburg, Karyn F. Siemasko, Jianping Gao
-
Patent number: 8617555Abstract: The present application provides a pharmaceutical composition for administration to a patient suffering from diabetes and other metabolic disorders, the composition comprises a) an activated-potentiated form of an antibody to human insulin receptor, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.Type: GrantFiled: July 15, 2011Date of Patent: December 31, 2013Inventor: Oleg Iliich Epshtein
-
Publication number: 20130336923Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.Type: ApplicationFiled: May 8, 2013Publication date: December 19, 2013Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Wayne A. Marasco, Agnes Lo, Chen Xu
-
Patent number: 8597650Abstract: It provides methods and pharmaceutical compositions comprising antagonists to the protein Bile Salt-Stimulated Lipase (BSSL) for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. It further relates to pharmaceutical compositions comprising BSSL antagonists and their use in methods for the prevention, prophylaxis and treatment of inflammatory diseases, such as rheumatoid arthritis. Suitable BSSL antagonists to be used according to the invention are BSSL antibodies.Type: GrantFiled: April 6, 2010Date of Patent: December 3, 2013Inventors: Olle Hernell, Susanne Lindquist, Lennart Gustav Lundberg
-
Patent number: 8592368Abstract: The present invention concerns a method for treating or reducing the likelihood of developing a respiratory syncytial virus (RSV) infection in a subject by administering an effective amount of an inhibitor of the janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway or the mitogen-activated kinase (MAPK)/extracellular signal-regulated kinase (ERK1/2) signaling pathway to the subject. Another aspect of the invention concerns a pharmaceutical composition that includes an inhibitor of JAK/STAT or MAPK/ERK signaling to the subject; and a pharmaceutically acceptable carrier. Another aspect of the invention concerns a method for identifying agents useful for treating or reducing the likelihood of developing an RSV infection.Type: GrantFiled: December 20, 2004Date of Patent: November 26, 2013Assignee: University of South FloridaInventor: Shyam S. Mohapatra
-
Patent number: 8586039Abstract: The invention relates to a modified antibody which contains two or more H chain V regions and two or more L chain V regions of monoclonal antibody and can transduce a signal into cells by crosslinking TPO receptor to thereby exert TPO agonist action. The modified antibody can be used as a TPO signal transduction agonist and, therefore, useful as a remedy for various diseases such as platelet-reduction-related blood diseases, thrombopenia following chemotherapy for cancer or leukemia, etc.Type: GrantFiled: September 6, 2011Date of Patent: November 19, 2013Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Masayuki Tsuchiya, Toshihiko Ohtomo, Naohiro Yabuta, Hiroyuki Tsunoda, Tetsuro Orita
-
Publication number: 20130302346Abstract: Antibodies that neutralize Notum Pectinacetylesterase are described, as well as compositions comprising them, and methods of their use to treat diseases and disorders affecting the bone.Type: ApplicationFiled: November 22, 2011Publication date: November 14, 2013Applicant: LEXICON PHARMACEUTICALS, INC.Inventors: Robert Joseph Brommage, JR., Xiao Feng, Seokjoo Hong, Gregory Landes, Jeff Liu, David George Potter, David Reed Powell
-
Patent number: 8568724Abstract: The present invention relates to binding molecules such as antibodies that specifically bind plasma coagulation factor XI and that inhibit factor XI activation and/or activity. The factor XI-binding molecules of the invention may used in methods for preventing or treating diseases, disorders and/or conditions that are mediated by factor XI activation and/or wherein inhibition of factor XI has a beneficial effect.Type: GrantFiled: June 19, 2012Date of Patent: October 29, 2013Inventor: Erik Hack
-
Patent number: 8568717Abstract: Described are single domain antibodies with a specificity for BACE1. More specifically, described are single variable-domain antibodies derived from camelids that bind to BACE1 and are capable of inhibiting the activity of BACE1. The antibodies can be used for research and medical applications. Specific applications include the use of BACE1-specific antibodies for the treatment of Alzheimer's disease.Type: GrantFiled: April 3, 2009Date of Patent: October 29, 2013Assignees: VIB VZW, Katholieke Universiteit Leuven, K.U. Leuven R&D, Vrije Universiteit BrusselInventors: Bart De Strooper, Els Marjaux, Lujia Zhou, Serge Muyldermans
-
Publication number: 20130280269Abstract: The present invention relates to methods that manipulate the level of interaction between the proteins Hsp70 and IRE1?. In particular, the invention relates to methods of manipulating this interaction in order to increase protein yield, and to methods of manipulating this interaction in order to treat diseases associated with abnormal apoptotic activity, including cancer and autoimmune diseases.Type: ApplicationFiled: June 8, 2011Publication date: October 24, 2013Applicant: National University of IrelandInventors: Afshin Samali, Sanjeev Gupta, Aysawaria Deepti
-
Publication number: 20130273062Abstract: Disclosed are CD39 antagonists that can inhibit the immunosuppressive effect of a CD39-expressing cancerous cell, and methods of using the CD39 antagonists.Type: ApplicationFiled: December 21, 2011Publication date: October 17, 2013Applicant: OREGA BIOTECHInventors: Armand Bensussan, Nathalie Bonnefoy-Berard, Jean-Francois Eliaou, Gilles Alberici, Jeremy Bastid
-
Publication number: 20130243784Abstract: The present invention provides methods for reducing lipoprotein(a) (Lp(a)) in patients. The methods of the present invention comprise selecting a patient who exhibits elevated serum Lp(a), and administering to the patient a pharmaceutical composition comprising a PCSK9 inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody such as the exemplary antibody referred to herein as mAb316P.Type: ApplicationFiled: September 12, 2012Publication date: September 19, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventor: Gary Swergold
-
Patent number: 8536313Abstract: A neutralizing monoclonal antibody specifically reacting with MMP13, a method of neutralizing enzyme activity of MMP13 and an immunological measuring method each using the antibody, as well as a diagnostic agent and a pharmaceutical composition containing the antibody, are provided. Various antibodies to MMP13 have been hitherto obtained, but an antibody having neutralizing activity against MMP13 has not been obtained. The present inventors intensively studied, as a result, found out a neutralizing antibody having specificity for MMP13, resulting in completion of the present invention.Type: GrantFiled: July 8, 2008Date of Patent: September 17, 2013Assignee: Shionogi & Co., Ltd.Inventors: Shoichi Naito, Junji Onoda, Akira Yamauchi, Yoshito Numata, Junji Kishono
-
Patent number: 8535668Abstract: A chimeric monoclonal antibody targeted at ricin, in which the light chain and heavy chain are such that: the constant region of the light chain and the constant region of the heavy chain are essentially made up respectively of the constant region of the light chain and the constant region of the heavy chain of human immunoglobulin, the variable region of the light chain and the variable region of the heavy chain include respectively the variable region of the light chain and the variable region of the heavy chain of macaque immunoglobulin, the monoclonal antibody not substantially inducing an immune response against chimeric antibodies.Type: GrantFiled: November 4, 2010Date of Patent: September 17, 2013Assignees: Etat Francais Represente par le Delegue General pour l'Armement, LFB BiotechnologiesInventors: Philippe Thullier, Alexandre Fontayne
-
Publication number: 20130236459Abstract: Provided are monospecific and bispecific antibodies that are useful as anti-neoplastic agents and that bind specifically to human IGF-1R and human ErbB3. Exemplary antibodies inhibit signal transduction through either or both of IGF-1R and ErbB3. Exemplary polyvalent proteins comprise at least one anti-IGF-1R binding site and at least one anti-ErbB3 binding site. In certain embodiments the binding sites may be linked through an immunoglobulin constant region. AntiErbB3 and anti-IGF-1R antibodies (e.g., monoclonal antibodies) are also provided.Type: ApplicationFiled: February 27, 2013Publication date: September 12, 2013Applicant: MERRIMACK PHARMACEUTICALS, INC.Inventors: Jason BAUM, Bryan JOHNSON, Alexey Alexandrovich LUGOVSKOY, Lihui XU, Neeraj KOHLI, Jonathan Basil FITZGERALD, Sharlene ADAMS
-
Patent number: 8524235Abstract: Antibodies and antigen binding fragments thereof that bind to human protein tyrosine phosphatase beta (HPTP?), and uses thereof.Type: GrantFiled: May 25, 2011Date of Patent: September 3, 2013Assignee: Aeripo Therapeutics Inc.Inventors: Rocco Jamie Rotello, Kevin Gene Peters, Michael Glenn Davis
-
Patent number: 8501181Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.Type: GrantFiled: December 28, 2011Date of Patent: August 6, 2013Assignee: Dyax Corp.Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
-
Patent number: 8496929Abstract: The present invention shows that site-specific antibodies to the (Na++K+)-ATPase exert a potent biological effect in cardiac myocytes and demonstrates a key structural region of the enzyme that participates in the regulation of cardiac contractility. These results establish an important link between a biological action and a precise molecular structure of the (Na++K+)-ATPase. Furthermore, the antibody-induced positive inotropic effect is independent of inactivation of the enzyme may reveal a novel mode for (Na++K+)-ATPase to regulate cardiac function. The data provide new molecular insights into the structural and functional relationship of the ubiquitous (Na++K+)-ATPase.Type: GrantFiled: June 6, 2002Date of Patent: July 30, 2013Inventor: Kai Y. Xu
-
Patent number: 8491905Abstract: Disclosed herein is a method of treating dry eye with a KLK-13 antibody.Type: GrantFiled: June 28, 2012Date of Patent: July 23, 2013Assignee: Allergan, Inc.Inventors: Michael E. Stern, Karyn F. Siemasko, Christopher Schaumburg, Jianping Gao
-
Publication number: 20130171163Abstract: The present invention relates to the regulation of angiogenesis and arteriogenesis by leukocyte antigen-related protein tyrosine phosphatase (LAR). The invention further relates to the use of inhibitors of LAR expression and/or activity to stimulate angiogenesis and/or arteriogenesis.Type: ApplicationFiled: August 5, 2011Publication date: July 4, 2013Inventors: Marschall Runge, Nageswara Madamanchi
-
Publication number: 20130156785Abstract: Methods for diagnosing inflammatory and/or cardiovascular diseases by assaying for Fibroblast Activation Protein (FAP) expression in a body fluid is provided as well as therapeutic means based thereon.Type: ApplicationFiled: August 29, 2011Publication date: June 20, 2013Applicant: UNIVERSITY OF ZURICHInventors: Chad Brokopp, Simon Hoerstrup
-
Patent number: 8466263Abstract: The invention provides scFv antibodies and monoclonal antibodies that bind to and decrease an activity of Carbonic Anhydrase IX (G250). Also provided are methods of treating and/or preventing cancer, such as renal clear cell cancer. Also provided are methods of identifying a carbonic anhydrase IX (G250) protein. The invention additionally provides methods of modifying immune effector cells, and the immune effector cells modified thereby.Type: GrantFiled: December 4, 2006Date of Patent: June 18, 2013Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Wayne A. Marasco, Agnes Lo, Chen Xu
-
Patent number: 8465742Abstract: A method of constructing a VHH library from an immunized camelid, using whole venom or an extract thereof There is also provided VHH antibody fragments isolated from a library produced in hyperimmunized llama These VHH antibody fragments were sequenced, and specifically bind ?-cobratoxin.Type: GrantFiled: December 4, 2009Date of Patent: June 18, 2013Assignee: University of GuelphInventors: J. Christopher Hall, Gabrielle Richard, Michael D. McLean
-
Patent number: 8460658Abstract: The present invention relates generally to the modulation of hyaluronan (HA) synthesis and degradation. The present invention further contemplates modulation of cellular proliferation, useful in the prophylaxis and/or treatment of inflammatory disorders including hyperproliferative conditions, such as but not limited to, cancer and psoriasis. The present invention is directed to compounds, agents, pharmaceutically active agents, medicaments, therapeutics, actives, drugs and the like which specifically target a portion of HAS which is accessible to the extracellular environment in malignant or inflammatory or proliferative cells but which portion is not accessible to the external environment in “normal” cells. A “normal” cell in this instance is a non-malignant, inflammatory or proliferative cell.Type: GrantFiled: June 13, 2011Date of Patent: June 11, 2013Assignee: Alchemia Oncology Pty LimitedInventors: Tracey J. Brown, Gary R. Brownlee
-
Patent number: 8455200Abstract: The present invention relates to a method of detecting the presence of cancer by measuring the level of enzyme activity and autoantibodies in the blood of an individual. In particular the present invention relates to methods for measurement of activated cAMP-dependent protein kinase A (PKA) activity and antibodies to PKA, a kit for activated PKA activity measurement, and the use of the measured levels of these analytes for determining the presence of cancer.Type: GrantFiled: October 14, 2010Date of Patent: June 4, 2013Assignee: Traxxsson, LLCInventors: Robert Puskas, Douglas Held
-
Patent number: 8444985Abstract: The present invention provides therapeutic compositions and methods for treating and preventing fungal disease or conditions including mucormycosis. The therapeutic methods and compositions of the invention include vaccine compositions having an FTR polypeptide or an antigenic fragment of the polypeptide; a vector including a nucleotide sequence that is substantially complimentary to at least 18 contiguous nucleotides of FTR sequence; an antisense; a small interfering RNA or an antibody inhibitor of FTR. The vaccine compositions of the invention can further include an adjuvant.Type: GrantFiled: March 19, 2010Date of Patent: May 21, 2013Assignee: Los Angeles Biomedical Research Institute at Harbor-ULCA Medical CenterInventors: Ashraf S. Ibrahim, Brad J. Spellberg, Yue Fu, John E. Edwards
-
Patent number: 8444970Abstract: The present invention relates to compositions and methods for prevention and treatment of diseases and conditions, particularly ocular diseases and conditions, characterized by aberrant fibrogenesis or scarring, inflammation, and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted. In one embodiment, the immune-derived moiety is a humanized monoclonal antibody that is reactive against sphingosine-1-phosphate.Type: GrantFiled: October 26, 2007Date of Patent: May 21, 2013Assignee: Lpath, Inc.Inventors: Roger A. Sabbadini, William A. Garland, Glenn L. Stoller
-
Patent number: 8435519Abstract: Activation sites on the alpha subunit of sodium potassium ATPase have been discovered. It has also been discovered that certain antibodies that bind to the alpha subunit of sodium potassium ATPase dramatically increase enzyme activity. There has never before been a report of precise activation sites or drug interaction sites for sodium potassium ATPase. Certain methods have also been discovered for treating or preventing diseases associated with low sodium potassium ATPase activity by administering antibodies, antibody fragments and small molecules that bind to the activation sites on the alpha subunit of sodium potassium ATPase.Type: GrantFiled: April 7, 2006Date of Patent: May 7, 2013Inventor: Kai Yuan Xu
-
Publication number: 20130110249Abstract: The present invention is directed to a monoclonal antibody that binds specifically to a Staphylococcus aureus glucosaminidase and inhibits in vivo growth of S. aureus. Also disclosed are monoclonal antibody binding portions, recombinant or hybridoma cell lines, pharmaceutical compositions containing the monoclonal antibody or binding portions thereof, and methods of treating 5*. aureus infection and osteomyelitis, and methods for introducing an orthopedic implant into a patient using the monoclonal antibody, binding portion, or pharmaceutical composition of the present invention.Type: ApplicationFiled: May 3, 2011Publication date: May 2, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Edward M. Schwarz, Mark A. Sullivan, John L. Daiss
-
Publication number: 20130095105Abstract: Disclosed are methods for treating eye diseases or conditions characterized by vascular instability, vascular leakage and neovacularization such as diabetic macular edema, age-related macular edema, choroidal neovascularization, diabetic retinopathy, trauma, ocular ischemia, retinal angiomatous proliferation, macular telangiectasia and uveitis.Type: ApplicationFiled: October 15, 2012Publication date: April 18, 2013Applicant: AERPIO THERAPEUTICS, INC.Inventor: AERPIO THERAPEUTICS, INC.
-
Publication number: 20130095101Abstract: Provided are methodology, compositions and kits to prevent and treat diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using processed lysyl oxidase or lysyl oxidase-like protein inhibitors, LOX inhibitors and LOXL inhibitors, or synergistic combinations of such inhibitors with therapeutic agents. Provided are methods for selecting tumor invasion, angiogenesis and metastasis inhibiting agents, by contacting cells in EMT states with candidate agents and detecting changes in such states; and methods, compositions, and kits for diagnosing or monitoring diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, using molecules or agents specifically recognizing processed LOX or LOXL. Provided are methods, compositions, medical devices, systems and kits for preventing or treating diseases and conditions associated with fibrosis, including pathological cardiovascular conditions and diseases, e.g.Type: ApplicationFiled: December 6, 2012Publication date: April 18, 2013Applicant: Gilead Biologics, Inc.Inventor: Gilead Biologics, Inc.
-
Publication number: 20130095113Abstract: The present disclosure provides methods for treating neurological disorders, generally involving modulating protein kinase D1 (PKD1) activity levels in a neuron or glial cell in an individual in need thereof. The present disclosure provides antibodies specific for PKD1. The present disclosure provides a genetically modified non-human mammal deficient in PKD1 activity.Type: ApplicationFiled: September 24, 2012Publication date: April 18, 2013Applicant: THE J. DAVID GLADSTONE INSTITUTESInventor: THE J. DAVID GLADSTONE INSTITUTES
-
Publication number: 20130095065Abstract: Disclosed are methods for treating Vascular Leak Syndrome and preventing cancer metastasis. Further disclosed are methods for treating vascular leakage due to inflammatory diseases, sepsis, cancer or the presence of pathogens.Type: ApplicationFiled: October 15, 2012Publication date: April 18, 2013Applicant: AERPIO THERAPEUTICS, INC.Inventor: AERPIO THERAPEUTICS, INC.
-
Patent number: 8398981Abstract: To provide a therapeutic drug for Alzheimer's disease and/or a cancer. The therapeutic drug for Alzheimer's disease and/or a cancer contains an anti-nicastrin antibody, a derivative of the antibody, or a fragment of the antibody or the derivative.Type: GrantFiled: October 19, 2011Date of Patent: March 19, 2013Assignees: The University of Tokyo, Perseus Proteomics Inc.Inventors: Takeshi Iwatsubo, Tatsuhiko Kodama, Takao Hamakubo, Taisuke Tomita, Ikuo Hayashi, Yasuomi Urano, Hiroko Iwanari, Masao Ohkuchi
-
Publication number: 20130064860Abstract: The invention provides a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to prostate-specific antigen, and b) an activated-potentiated form of an antibody to endothelial NO-synthase. Various embodiments and variants are provided. The invention provides methods of treating benign prostatic hyperplasia and erectile dysfunctions and various methods of administration comprising administering a pharmaceutical composition comprising a) an activated-potentiated form of an antibody to prostate-specific antigen, and b) an activated-potentiated form of an antibody to endothelial NO-synthase.Type: ApplicationFiled: July 15, 2011Publication date: March 14, 2013Inventor: Oleg Iliich Epshtein